This study is not accepting new patients

Expanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release

a study on Multiple Myeloma

Summary

Eligibility
for people ages 18 years and up (full criteria)
Dates
study started
Principal Investigator
by Sarah M. Larson, MD
Headshot of Sarah M. Larson
Sarah M. Larson

Description

Summary

This study is designed to evaluate the safety and efficacy of nonconforming idecabtagene vicleucel (ide-cel) in participants with multiple myeloma per the approved prescribing information. This is an expanded access protocol (EAP) to be conducted at Risk Evaluation and Mitigation Strategies (REMS) qualified sites approved for commercial administration of idecabtagene vicleucel and where the EAP is authorized to be conducted for use of nonconforming idecabtagene vicleucel.

Non-conforming idecabtagene vicluecel is idecabtagene vicleucel that does not meet commercial release specifications but may be acceptable for use as an investigational product in the Expanded Access Protocol setting.

Official Title

Expanded Access Protocol (EAP) for Patients Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release

Keywords

Multiple Myeloma, BB2121, Expanded Access, idecabtagene vicleucel, nonconforming, CAR T, EAP, Pre-Approval Access, Nonconforming idecabtagene vicleucel

Eligibility

You can join if…

Open to people ages 18 years and up

  • Had a participant-specific batch of Idecabtagene vicleucel (ide-cel) manufactured intended for commercial treatment; however, the final manufactured product was nonconforming and did not meet commercial release criteria
  • Remanufacturing is deemed not feasible or clinically inappropriate per assessment of the treating physician in discussion with the participant
  • Clinically stable

You CAN'T join if...

  • Has a hypersensitivity to the active substance or to any of the excipients
  • No experience of a significant worsening in clinical status that would, in the opinion of the treating physician, either increase the risk of Adverse Events associated with lymphodepleting chemotherapy, or exclude them from treatment with nonconforming Idecabtagene vicleucel (ide-cel)
  • Has any condition and/or laboratory abnormality that places the participant at unacceptable risk if he/she were to participate in the Expanded Access Protocol based on the Investigator's judgement

Other protocol-defined inclusion/exclusion criteria apply

Lead Scientist at UCLA

  • Sarah M. Larson, MD
    HS Associate Clinical Professor, Medicine. Authored (or co-authored) 21 research publications

Details

Status
not accepting new patients
Start Date
Sponsor
Celgene
Links
BMS Clinical Trial Information BMS Clinical Trial Patient Recruiting FDA Safety Alerts and Recalls Sign up for this study
ID
NCT04771078
Study Type
Expanded Access
Last Updated
Contact us about this trial